| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/15/2006 | US7090848 immunology; genetic vaccines |
| 08/15/2006 | US7090847 antibody/fragment binds interleukin or fusion protein; immunology; tissue-targeted therapy |
| 08/15/2006 | US7090846 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body |
| 08/15/2006 | US7090845 Diagnosis and treatment of hepatic disorders |
| 08/15/2006 | US7090842 antigen-binding fragment comprises immunoglobulin variable region light chains and heavy chains, produced by hybridoma; fusion proteins |
| 08/15/2006 | US7090835 Modified colony stimulating factor for treatment of hematopoietic disorder |
| 08/15/2006 | US7090834 which exhibit improved binding; site directed mutagenesis; host cells |
| 08/15/2006 | CA2287267C Improved methods for processing activated protein c |
| 08/15/2006 | CA2266622C Hyaluronic drug delivery system |
| 08/15/2006 | CA2258554C Method for providing dense particle compositions for use in transdermal particle delivery |
| 08/15/2006 | CA2238871C Method of using beta-interferons to treat restenosis |
| 08/15/2006 | CA2215476C Arginine analogues having nitric oxide synthase inhibitor activity |
| 08/15/2006 | CA2211612C [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides |
| 08/15/2006 | CA2155334C Pulmonary administration of erythropoietin |
| 08/15/2006 | CA2107439C Phospholipid derivatives containing phosphorous, arsenic, antimony or bismuth |
| 08/10/2006 | WO2006084141A2 Suspension formulation of interferon |
| 08/10/2006 | WO2006084139A2 An implantable interferon-containing device |
| 08/10/2006 | WO2006084095A1 Compositions and methods for less immunogenic protein formulations |
| 08/10/2006 | WO2006084058A2 Method for treating gefitinib resistant cancer |
| 08/10/2006 | WO2006083947A2 Compositions and methods for treating fibrotic disorders |
| 08/10/2006 | WO2006083927A2 Antimicrobial agent |
| 08/10/2006 | WO2006083906A2 Compositions containing the anti-angiogenic phscn-peptide |
| 08/10/2006 | WO2006083873A2 Screening and therapeutic methods for treating circadian rhythm disorders |
| 08/10/2006 | WO2006083761A2 Solvent/polymer solutions as suspension vehicles |
| 08/10/2006 | WO2006083562A2 Method and multicomponent conjugates for treating cancer |
| 08/10/2006 | WO2006083533A2 Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| 08/10/2006 | WO2006083455A1 Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
| 08/10/2006 | WO2006083439A2 Method for lowering serum homocysteine |
| 08/10/2006 | WO2006083276A2 Interferon-alpha polypeptides and conjugates |
| 08/10/2006 | WO2006083266A1 Inhibitors of bacterial type iii protein secretion systems |
| 08/10/2006 | WO2006083183A1 Use of myostatin (gdf-8) antagonists for treatment of sarcopenia (age-related muscle-wasting) |
| 08/10/2006 | WO2006083182A1 Use of myostatin (gdf-8) antagonists for improving wound healing and preventing fibrotic disease |
| 08/10/2006 | WO2006083090A1 Pharmaceutical composition for preventing and treating restenosis comprising peroxiredoxin 2 protein as an active ingredient and composition for screening therapeutics of restenosis comprising peroxiredoxin 2 gene or its protein product, and method for screening therapeutics of restenosis using said composition |
| 08/10/2006 | WO2006083051A1 G6pd enzyme inhibitor and method for treating obesity using the same |
| 08/10/2006 | WO2006082824A1 Matrix-type enteric coated sustained release composition |
| 08/10/2006 | WO2006082609A1 Human ngf-like protein isolated from eisenia foetida an uses thereof |
| 08/10/2006 | WO2006082517A1 Pyy agonists and uses thereof |
| 08/10/2006 | WO2006082451A1 Bioactive compounds |
| 08/10/2006 | WO2006082435A1 Method and use of interferon compositions for the treatment of avian influenza |
| 08/10/2006 | WO2006082434A1 Caspase-3 substrate comprising imaging agents |
| 08/10/2006 | WO2006082304A2 Novel peptides which interact with anti-apoptotic members of the family of bcl-2 proteins and use thereof |
| 08/10/2006 | WO2006082303A1 Motif of beclin protein which interacts with anti-apoptotic members of the family of bcl-2 proteins and use thereof |
| 08/10/2006 | WO2006082245A1 Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand |
| 08/10/2006 | WO2006082222A1 Compositions comprising epigallocatechin gallate and protein hydrolysate |
| 08/10/2006 | WO2006082205A1 Insulin derivatives |
| 08/10/2006 | WO2006082204A1 Insulin derivatives |
| 08/10/2006 | WO2006081826A2 Survivin peptide vaccine |
| 08/10/2006 | WO2006081669A1 Anti-t cell and autoantigen treatment of autoimmune disease |
| 08/10/2006 | WO2006081620A1 Cd4+ cd25+ t-cells activated to a specific antigen |
| 08/10/2006 | WO2006069240A3 Composition and treatment methods for coronary artery disease |
| 08/10/2006 | WO2006066258A3 Lipoconjugation of peptides |
| 08/10/2006 | WO2006066020A3 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 08/10/2006 | WO2006060920A8 Novel uses of egf |
| 08/10/2006 | WO2006059069A3 Ion channel |
| 08/10/2006 | WO2006055531A3 Peptidomimetic polymers for antifouling surfaces |
| 08/10/2006 | WO2006050861A3 Statine derivatives for the treatment of alzheimer's disease |
| 08/10/2006 | WO2006050262A3 Compositions and methods for modification of biomolecules |
| 08/10/2006 | WO2006044614A3 Anti-angiogenic peptides and methods of use thereof |
| 08/10/2006 | WO2006036879A3 Chimeric gb virus b (gbv-b) |
| 08/10/2006 | WO2006036550A3 Listeria-based and llo-based vaccines |
| 08/10/2006 | WO2006025882A3 Absorption enhancers for drug administration |
| 08/10/2006 | WO2006023714A3 Dithiocarbamate derivatives and their use for treating cancer |
| 08/10/2006 | WO2006019429A3 Methods of identifying and using agents that increase inhibition of or resistance to hcv infection |
| 08/10/2006 | WO2006018418A3 Antiangiogenic peptides |
| 08/10/2006 | WO2006015057A3 C-terminally truncated interferon |
| 08/10/2006 | WO2006014872A3 Novel processes for stereoselective synthesis of trans isatx 247 |
| 08/10/2006 | WO2005123114A3 Silk-based drug delivery system |
| 08/10/2006 | WO2005122739A3 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
| 08/10/2006 | WO2005118621A3 Omi pdz modulators |
| 08/10/2006 | WO2005117944A3 Hsp20 inhibits amyloidogenesis and neurotoxicity |
| 08/10/2006 | WO2005115455A3 Methods and reagents for the treatment of immunoinflammatory disorders |
| 08/10/2006 | WO2005110493A3 Methods for delivering mbd peptide-linked agent into cells under conditions of cellular stress |
| 08/10/2006 | WO2005099337A3 Therapeutic peptides |
| 08/10/2006 | WO2005092073A3 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| 08/10/2006 | WO2005086663A3 Polypeptides for inducing a protective immune response against staphlococcus aureus |
| 08/10/2006 | WO2005085280A3 HUMAN cDNA CLONES COMPRISING POLYNUCLEOTIDES ENCODING POLYPEPTIDES AND METHODS OF THEIR USE |
| 08/10/2006 | WO2004050894A3 Heart failure gene determination and therapeutic screening |
| 08/10/2006 | WO2003074004A3 Method of producing antigens |
| 08/10/2006 | WO2003065999A3 Proliferated cell lines and uses thereof |
| 08/10/2006 | WO2003017920A3 Protective factors against inflammation, burns and noxious stimuli |
| 08/10/2006 | US20060179496 Nucleic acid sequences differentially expressed in cancer tissue |
| 08/10/2006 | US20060179493 Transgenically produced non-secreted proteins |
| 08/10/2006 | US20060179492 Method of inhibiting neural transmission mediated by serotonin-2a and enhancing sensorimotor gating |
| 08/10/2006 | US20060178518 3'-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 08/10/2006 | US20060178504 Eotaxin: eosinophil chemotactic cytokine |
| 08/10/2006 | US20060178503 Antibody to an integrin heterodimer and/or a subunit thereof |
| 08/10/2006 | US20060178421 Hydrogenation catalysts |
| 08/10/2006 | US20060178337 Method for diagnosing aplasia of corpus callosum |
| 08/10/2006 | US20060178333 Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof |
| 08/10/2006 | US20060178331 Antisense oligonucleotides targeting folate receptor alpha, and the use thereof |
| 08/10/2006 | US20060178329 Rna sequence for therapy of cancer; control degradation and block transscription of messenger Rna that is translation product of target gene |
| 08/10/2006 | US20060178327 Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro |
| 08/10/2006 | US20060178326 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 08/10/2006 | US20060178324 Lipophilic derivatives of double-stranded ribonucleic acid |
| 08/10/2006 | US20060178317 Methods of increasing endogenous erythropoietin (EPO) |
| 08/10/2006 | US20060178316 Methods of increasing endogenous erythropoietin (EPO) |
| 08/10/2006 | US20060178315 For therapy of immune or autoimmune diseases |
| 08/10/2006 | US20060178314 Methods and compositions for treating atheroma, tumors and other neoplastic tissues |
| 08/10/2006 | US20060178313 Use of a polypeptide for treatment of pruritus in animals |
| 08/10/2006 | US20060178312 Process for the production of melagatran |